Single Cell Proteomics | The Superhuman Cell Company

The Superhuman Cell
Company

Superhuman cell biology is changing the course of advanced medicines and complex diseases that have hampered humanity. Our systems and customers are leveraging the super human cells in all of us to advance human health. Our systems, which uniquely reveal these superhuman cells through single-cell & proteomic innovations, are enabling customers to advance the future of medicines against complex disease.

Request a Quote

Proteomic Products

Superhuman Cell Biology Has Been Published in 100 Publications

View All Publications

Introducing the Superhuman Cell Library

The Superhuman Cell Library provides the functional proteomic drivers of each cell, using IsoPlexis' unique functional cell phenotyping, which has been shown in the literature to underlie various long-term responses and disease states in major areas of human health.

Introducing Duomic

For the first time, find the underlying genetic code of the proteomically driven superhuman cells that drive response to complex disease. This information can be used to recode and replicate superhero cells to drive the future of high resolution discovery biology.

Our Systems Detect Superhuman Cells and
Their Proteomic Environment

Capture the “super” single cells with the highest multiplexed proteomic signatures

Leverage wide bodies of peer reviewed data demonstrating the predictive power of super cells

Access data real time with advanced analytic visualizations

Access Superhuman Cells and their Benefits Today

Utilize the single cell functional protomics hub to
accelerate advanced medicines for human health

Learn More

Our Solutions

The Products Driving Our Superpowered Biology

Reveal the Superhero and
Villain Cells in All of Us

Functional Immune Landscaping

The Single-Cell Secretome: Cytokines, Chemokines, Growth Factors

Website_Homepage Icons__-electical circuits inside

Unlock the Electric
Wiring Behind Supercells

Intracellular Signaling Omics

The Single-Cell Phosphoproteome: Kinases, Translation & Transcription Factors

Unlock the Genetic Code
Behind Superhero Cells

Duomic

Single-Cell Functional Proteomics and Transcriptomics

Reveal the Bulk
Proteomic Environment

High-plex Walk-Away Immunoassays

Easily Accessible, Yet Comprehensive Bulk Proteome

Technology

Superhuman Cell Biology Built on a Strong Foundation

Superhuman Biology

Immune
Cells

Tumor

Proteomics, Reimagined to uniquely detect our most powerful cells.

Explore Our Biology

Instrument Virtual Demo

The entire ELISA proteomics workflow, sample to answer.

Take the Virtual Tour

Data Visualization Tour

IsoSpeak Software: Same day visualizations and insights.

Tour the Visualizations

Publications

See how top researchers are using our technology to predict durable responses and unlock pre-clinical meaning.

View All Publications

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

Yapeng Su et al., Cell. 2022.

View Publication

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Jay Y. Spiegel et al., Nature Medicine. 2021.

View Publication

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Adi Diab et al., Journal of Clinical Oncology. 2021.

View Publication

Areas of Interest

See how we can shift the paradigms in your programs

Cancer
Immunology

IsoPlexis’ Functional Immune landscaping for liquid T cell biopsies is showing which therapies work with which patients with unique insights.

Cell
Therapy

Quality Analytics with IsoPlexis’ functional immune landscaping are shaping the future of cell therapy and enabling more efficient manufacturing, higher quality cell therapies, and improved patient outcomes.

Infectious
Disease

COVID-19 and other complex diseases are being advanced with IsoPlexis’ functional immune-landscaping and high-plex automated immunoassays to speed insights.

Inflammation

IsoPlexis’ high-plex automated immunoassays and functional immune landscaping are providing immediate insights into the drivers of immune inflammation.

Targeted
Therapies

IsoPlexis’ intracellular signaling omics are revealing mechanisms of the functional cellular adaptations leading to resistance and providing insights for the development of better targeted therapies.

Updates

Enabling a New Era of Precision Medicine

Latest Customer Stories View Blog

Blog Post_Nature Communications Using Single-Cell Secretomics_kr_jt (1)

Jun 24

Published in Nature Communications: Using Single-Cell Secretomics to Characterize the Functional Effects of a Novel CAR-T Expansion Method

Cellular and Regenerative Medicine

Jun 14

Published in Science Advances: IsoPlexis’ Single-Cell Functional Proteomics Helps Identify Biomarkers of CAR-T Response and Relapse

Cellular and Regenerative Medicine

Blog Post_Using Single-Cell Secretomics to Understand Dual-Targeted CAR-T_kr3

Jun 10

Published in Cytotherapy: Using Single-Cell Secretomics to Understand Function in Dual-Targeted CAR-T Therapies

Cell Therapy | Cellular and Regenerative Medicine

Featured Events All Events

Immuno-Oncology Summit Europe

Conference

May 23-25, 2022 | London, UK

View Event

SITC

Conference

November 9-13, 2022 | Boston, MA

View Event

ASH

Conference

December 10-13, 2022 | New Orleans, LA

View Event

Featured Content

The IsoSpark Brochure

Accelerate immune medicine across research areas & high-impact applications. All in one, beautifully designed and intuitive system that fits on any lab bench. Across all applications, discover immune profiling insights unattainable with any other system.

Download Now

quote-isospark-solid-gradient-smooth-green@2x

Trusted Worldwide

We innovated the only way to measure the true function of each cell and identify the rare subsets of superpowered cells driving response.

As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T therapy before treatment.

Christine Brown, PHD

City of Hope

The future is very powerful here. One can study autoimmunity and cancer biology, one can take out from the blood single cells, one can analyze those cells and get an overall picture from integrating that analysis.

Arnold Levine, PHD

Professor Emeritus, Simons Center for Systems Biology, Institute for Advanced Study

Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI… can we start to differentiate products.

Marco L Davila, MD, PHD

Moffitt Cancer Center

We see potential in utilizing IsoPlexis’ single-cell system to help provide deeper resolution into the functional impacts of our therapeutics… This collaboration will enable us to apply the sensitivity of this solution to further our understanding of patient-specific responses to our immune therapies.

Jon Zalevsky, PHD

Chief Scientific Officer, Nektar Therapeutics

Through this research, we were able to highlight the important role a functionally versatile subpopulation of CAR-T cells may play in the fight against cancer. This could lead to new methods to optimize T-cell products.

Adrian Bot, MD, PHD

Vice President, Translation Sciences, Kite

Current assays that rely on a single-plex ELISA or even multiparametric flow cytometry don’t give you the level of resolution that the IsoPlexis platform can provide.

John Rossi

Director of Translational Sciences at Kite

“The best way to predict the future is to invent it.”

— Alan Kay

Spark the Next Breakthrough

Speak to an Expert